Pharma News

Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company, has announced a strong start to FY2026-27, reporting double-digit revenue growth in the first quarter ended June 30, 2026. Robust performance in the domestic formulations business and continued momentum in its innovative medicines portfolio helped the company deliver higher sales and profitability despite softer demand in the U.S. generics market.

Sun Pharma announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing.

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION® Injection, 100 mg/mL market3 achieved annual sales of approximately 1.6 billion USD.

Johnson & Johnson (J&J) has announced a proposed 5.5 billion USD settlement aimed at resolving nearly all remaining U.S. lawsuits alleging that its talc-based products caused ovarian cancer, marking one of the largest mass-tort settlement efforts in the company's history. The proposed agreement covers approximately 76,000 pending claims and will take effect only if at least 95% of eligible claimants agree to participate.

Sandoz, the global leader in affordable medicines, confirms that the Agência Nacional de Vigilância Sanitária (ANVISA) has granted marketing authorisation for Owozy® (semaglutide), which Sandoz will commercialise in Brazil in partnership with Adalvo.

Engineered Gut Bacteria Show Potential as a New Weapon Against Pancreatic CancerResearchers have developed a genetically engineered probiotic bacterium that could offer a promising new approach for treating pancreatic cancer, one of the deadliest forms of cancer with limited therapeutic options. The study demonstrates that a modified strain of Bifidobacterium longum, a naturally occurring gut bacterium, can selectively colonize pancreatic tumors and stimulate a potent anti-tumor immune response.

Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Oriflame India's manufacturing business, marking its entry into the fast-growing color cosmetics manufacturing sector while significantly expanding its personal care and wellness portfolio.

The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen, the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for up to 12 hours of pain relief. The approval introduces a new over-the-counter (OTC) option for consumers seeking long-lasting, dual-action pain management without a prescription.